<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Obiltoxaximab (United States: Availability limited to Strategic National Stockpile distribution): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Obiltoxaximab (United States: Availability limited to Strategic National Stockpile distribution): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Obiltoxaximab (United States: Availability limited to Strategic National Stockpile distribution): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="107693" href="/d/html/107693.html" rel="external">see "Obiltoxaximab (United States: Availability limited to Strategic National Stockpile distribution): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="110539" href="/d/html/110539.html" rel="external">see "Obiltoxaximab (United States: Availability limited to Strategic National Stockpile distribution): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F46304349"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity and anaphylaxis:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity and anaphylaxis have been reported during the intravenous infusion of obiltoxaximab. Due to the risk of hypersensitivity and anaphylaxis, obiltoxaximab should be administered in monitored settings by personnel trained and equipped to manage anaphylaxis. Monitor individuals who receive obiltoxaximab closely for signs and symptoms of hypersensitivity reactions throughout the infusion and for a period of  time after administration. Stop obiltoxaximab infusion immediately and treat appropriately if hypersensitivity or anaphylaxis occurs.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F57294484"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Anthim</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F46304352"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antidote;</li>
<li>
                        Monoclonal Antibody</li></ul></div>
<div class="block doa drugH1Div" id="F46440343"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3fa44293-5639-44a4-a1e5-a1900644cd79">Anthrax, inhalational</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anthrax, inhalational (treatment and prophylaxis):</b>
<b>IV:</b>
<b>Note:</b> Premedicate with diphenhydramine prior to infusion.</p>
<p style="text-indent:-2em;margin-left:4em;">≤40 kg: 24 mg/kg/dose as a single dose.</p>
<p style="text-indent:-2em;margin-left:4em;">&gt;40 kg: 16 mg/kg/dose as a single dose.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990566"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, a small clearance rate (L/day) suggests that there is minimal renal clearance (Hou 2017).</p></div>
<div class="block doha drugH1Div" id="F50987914"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling</p></div>
<div class="block doe drugH1Div" id="F46440345"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing</p></div>
<div class="block dop drugH1Div" id="F46440344"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="110539" href="/d/html/110539.html" rel="external">see "Obiltoxaximab (United States: Availability limited to Strategic National Stockpile distribution): Pediatric drug information"</a>)</p>
<p style="text-indent:0em;margin-top:0em;display:inline">
<b>Note:</b> Premedicate with diphenhydramine prior to infusion.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b1dc65f3-53f3-4240-b457-f4372086b080">Anthrax, inhalational; treatment and prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anthrax, inhalational; treatment and prophylaxis: </b>Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">≤15 kg: IV: 32 mg/kg as a single dose</p>
<p style="text-indent:-2em;margin-left:4em;">&gt;15 kg to 40 kg: IV: 24 mg/kg as a single dose</p>
<p style="text-indent:-2em;margin-left:4em;">&gt;40 kg: IV: 16 mg/kg as a single dose</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51131620"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block dohp drugH1Div" id="F51131621"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block adr drugH1Div" id="F46361040"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (8% to 16%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest discomfort (&lt;2%), chest pain (&lt;2%), palpitations (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (4%), skin rash (7%), urticaria (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Vomiting (&lt;2%), xerostomia (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Abnormal lymphocytes (decreased: &lt;2%), decreased neutrophils (&lt;2%), decreased white blood cell count (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Bruising at injection site (3%), erythema at injection site (4%), infusion-site pain (2%), skin discoloration at injection site (&lt;2%), swelling at injection site (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (&lt;2%), fatigue (&lt;2%), voice disorder (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Increased creatine phosphokinase in blood specimen (&lt;2%), limb pain (2%), musculoskeletal pain (&lt;2%), myalgia (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (3% to 8%), cyanosis (&lt;2%), dyspnea (&lt;2%), nasal congestion (2%), oropharyngeal pain (&lt;2%), paranasal sinus congestion (&lt;2%), rhinorrhea (3%), throat irritation (3%), upper respiratory tract infection (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Hypersensitivity: Anaphylaxis</p></div>
<div class="block coi drugH1Div" id="F46304355"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F46440333"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: <b>[US Boxed Warning]: Hypersensitivity or anaphylactic reactions (eg, rash/urticaria, cough, dyspnea, cyanosis, postural dizziness, chest discomfort) may occur. Administer in a monitored setting; monitor patients closely for signs and symptoms of hypersensitivity during and after the infusion. If hypersensitivity or anaphylaxis occurs, discontinue the infusion immediately and treat appropriately. </b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). Refer to manufacturer's labeling.</p></div>
<div class="block geq drugH1Div" id="F57294482"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block dinfoc drugH1Div" id="F57294485"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Anthim: 600 mg/6 mL (6 mL) [contains polysorbate 80]</p></div>
<div class="block accres drugH1Div" id="F51193338"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">Obiltoxaximab (ANTHIM) is not available for general public use. All supplies are currently owned by the federal government for inclusion in the Strategic National Stockpile and for use by the US military.</p></div>
<div class="block adm drugH1Div" id="F46440348"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IV: Premedication with diphenhydramine is recommended. Administer prepared solution (IV infusion bag or syringe) using a 0.22 micron inline filter over 1 hour and 30 minutes. Flush the line with NS at the end of the infusion.</p></div>
<div class="block admp drugH1Div" id="F52614643"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">IV: Must be diluted prior to administration. Administer over 90 minutes using a 0.22 micron inline filter. Flush the line with NS at the end of the infusion. Premedication with diphenhydramine is recommended.</p></div>
<div class="block use drugH1Div" id="F46304354"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;margin-left:0em;display:inline">
<b>Anthrax, inhalational:</b></p>
<p style="text-indent:-2em;margin-left:2em;">Treatment of inhalational anthrax due to <i>Bacillus anthracis</i> in combination with appropriate antibacterial drugs</p>
<p style="text-indent:-2em;margin-left:2em;">Prophylaxis of inhalational anthrax due to <i>B. anthracis</i> when alternative therapies are not available or not appropriate</p>
<p style="text-indent:-2em;margin-left:4em;">Limitations of use: Should only be used for prophylaxis when the benefit for prevention of inhalational anthrax outweighs the risk of hypersensitivity and anaphylaxis.</p></div>
<div class="block cyt drugH1Div" id="F46361113"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F46361110"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F46440331"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Obiltoxaximab is a chimeric monoclonal antibody (IgG<sub>1</sub>). Placental transfer of human IgG is dependent upon the IgG subclass, maternal serum concentrations, birth weight, and gestational age, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis (Palmeira 2012; Pentsuk 2009).</p>
<p style="text-indent:0em;margin-top:2em;">Untreated maternal anthrax infection has a high risk of maternal, fetal, and neonatal death. In general, guidelines for the prophylaxis and treatment of inhalational anthrax following exposure to <i>Bacillus anthracis</i> in pregnant and postpartum women are the same as nonpregnant adults (Meaney-Delman 2014).</p></div>
<div class="block brc drugH1Div" id="F46440332"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if obiltoxaximab is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">Obiltoxaximab is a chimeric monoclonal antibody (IgG<sub>1</sub>). Maternal IgG is present in breast milk. According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. In general, guidelines for the prophylaxis and treatment of inhalational anthrax following exposure to <i>Bacillus anthracis</i> in lactating women are the same as nonpregnant adults (Meaney-Delman 2014).</p></div>
<div class="block mop drugH1Div" id="F46440350"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor patients closely for signs and symptoms of hypersensitivity during and after the infusion.</p></div>
<div class="block pha drugH1Div" id="F46440338"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Obiltoxaximab is a monoclonal antibody that binds the free protective antigen component of <i>B. anthracis</i> toxin thereby preventing the intracellular entry of the anthrax lethal factor and edema factor, the enzymatic toxin components responsible for the pathogenic effects of anthrax toxin.</p></div>
<div class="block phk drugH1Div" id="F46440340"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Greater than plasma volume (eg, some tissue distribution).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion:  Minimal renal elimination</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F54091526"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Obiltoxaximab sfl</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/obiltoxaximab-united-states-availability-limited-to-strategic-national-stockpile-distribution-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Anthim.1">
<a name="Anthim.1"></a>Anthim (obiltoxaximab) [prescribing information]. Parsippany, NJ: Elusys Therapeutics Inc; June 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199 <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/obiltoxaximab-united-states-availability-limited-to-strategic-national-stockpile-distribution-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28573869">
<a name="28573869"></a>Hou AW, Morrill AM. Obiltoxaximab: adding to the treatment arsenal for Bacillus anthracis infection. <i>Ann Pharmacother</i>. 2017;51(10):908-913. doi:10.1177/1060028017713029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/obiltoxaximab-united-states-availability-limited-to-strategic-national-stockpile-distribution-drug-information/abstract-text/28573869/pubmed" id="28573869" target="_blank">28573869</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47:313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/obiltoxaximab-united-states-availability-limited-to-strategic-national-stockpile-distribution-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43:172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/obiltoxaximab-united-states-availability-limited-to-strategic-national-stockpile-distribution-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24457117">
<a name="24457117"></a>Meaney-Delman D, Zotti ME, Creanga AA, et al; Workgroup on Anthrax in Pregnant and Postpartum Women. Special considerations for prophylaxis for and treatment of anthrax in pregnant and postpartum women. <i>Emerg Infect Dis</i>. 2014;20(2). doi:10.3201/eid2002.130611<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/obiltoxaximab-united-states-availability-limited-to-strategic-national-stockpile-distribution-drug-information/abstract-text/24457117/pubmed" id="24457117" target="_blank">24457117</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22235228">
<a name="22235228"></a>Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. <i>Clin Dev Immunol</i>. 2012;2012:985646. doi:10.1155/2012/985646<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/obiltoxaximab-united-states-availability-limited-to-strategic-national-stockpile-distribution-drug-information/abstract-text/22235228/pubmed" id="22235228" target="_blank">22235228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19626656">
<a name="19626656"></a>Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. <i>Birth Defects Res B Dev Reprod Toxicol</i>. 2009;86(4):328-344. doi:10.1002/bdrb.20201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/obiltoxaximab-united-states-availability-limited-to-strategic-national-stockpile-distribution-drug-information/abstract-text/19626656/pubmed" id="19626656" target="_blank">19626656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/obiltoxaximab-united-states-availability-limited-to-strategic-national-stockpile-distribution-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 107447 Version 63.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
